WASHINGTON — Lawmakers will wade through more than 100 potential amendments when the Senate Finance Committee takes up its sweeping new drug pricing package on Thursday.

Some of the amendments could significantly rework the package, like an amendment from Sens. Pat Toomey (R-Pa.) and Pat Roberts (R-Kan.) that would eliminate the controversial provisions in the bill that would restrict drug makers from raising prices beyond the rate of inflation. A separate amendment from Sen. John Cornyn (R-Texas) would only allow that provision to go into effect if HHS certifies it won’t lead to higher launch prices.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy